(“Cipla”) today announced its partnership with, Eli Lilly and Company (India) Pvt. Ltd., a 100% subsidiary of Eli Lilly and Company, a global multinational pharmaceutical leader, for the marketing and distribution of Lilly’s BASAGLAR® (insulin glargine injection) in India. Under this agreement, Lilly’s BASAGLAR® that is manufactured by Lilly will be marketed and distributed in India by Cipla. Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. BASAGLAR® is long acting insulin glargine approved in India through the biosimilar pathway and is indicated for the treatment of type 1 and type 2 diabetes patients above 2 years of age. BASAGLAR® is to be prescribed by medical practitioners in once a day dosage form at the same time every day and is available in India in the form of a prefilled pen and cartridges.
BASAGLAR® should not be used to treat diabetic ketoacidosis. BASAGLAR® should not be used during episodes of low blood sugar (hypoglycemia) or in people with an allergy to insulin glargine or any of the ingredients in BASAGLAR®.
Umang Vohra, MD & Global CEO, Cipla Ltd. said, “Diabetes continues to be a focus area for Cipla and with the launch of strong brand like BASAGLAR®, Cipla will be at the forefront of providing a holistic diabetes care with the most comprehensive portfolio across orals and injectables. Cipla’s focus continues to revolve around care continuum approach for the patients it serves and create greater access to high quality treatment and medication.”
Luca Visini, Managing Director, Lilly India said, “Lilly is very happy to collaborate with a partner of high capabilities and with a common vision of contributing to making life better to patients across India. This strategic partnership leverages Lilly’s commitment to bring innovation to people suffering from diabetes in India and Cipla’s strong on-ground footprint across the country.”
He added, “While insulin has been a mainstay of diabetes treatment for many years, when it comes to initiating basal insulin therapy, people with diabetes still face several emotional and practical challenges. We believe that the launch of BASAGLAR®, with its support for healthcare professionals and patients, is an important milestone in our journey to contribute to better diabetes care in India through our portfolio of innovative therapies and solutions”. Cipla expects to start commercialising BASAGLAR® in India by end of the year 2018.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For over 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across
more than 80 countries. Our portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally. Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001. Cipla’s research and development focuses on developing innovative products and drug delivery systems.